BEAM News
Archived Headlines
- Burning Up: Hot Streak for Biotechs Continues in 2020 02/06/20
- Beam Therapeutics prices upsized IPO at $17, the high end of the range 02/06/20
- Gene editing biotech Beam Therapeutics upsizes proposed IPO share offering by 48% 02/05/20
- US IPO Week Ahead: Beds in boxes and a billion-dollar drug developer featured in diverse 7-IPO week 01/31/20
- Gene editing biotech Beam Therapeutics sets terms for $100 million IPO 01/27/20
See more
US IPO Week Ahead: Chinese EVs and US tax software lead a diverse 7 IPO week
Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex (VERX). A handful of companies could join the IPO calendar in the coming week, including leading mortgage lender Rocket Companies...read more
No trial, no problem: Biggest week for preclinical biotech IPOs ever
Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week. Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its...read more
US IPO Week Ahead: One biotech to close out February
Preclinical biotech Passage Bio (PASG) is the only IPO set to price in the coming week. Passage Bio plans to raise $126 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint, Passage Bio would command a...read more
US IPO Weekly Recap: Schrödinger shines while the market sleeps on Casper in 7-IPO week
Seven IPOs and one SPAC entered public market this past week. Life sciences software maker Schrödinger (SDGR) rocketed in its debut and contract researcher PPD (PPD) completed 2020’s second billion-dollar deal,...read more